Omnicell completes Ateb acquisition
MOUNTAIN VIEW, Calif. — Omnicell on Wednesday announced that it had completed its acquisition of Ateb and its Canadian affiliate Ateb Canada. The company said the $41 million acquisition reinforces its commitment to improving patient care and outcomes by simplifying management of chronic conditions through increases access to adherence solutions.
With the acquisition, Omnicell adds to its portfolio Ateb’s Time My Meds, an integrated medication synchronization program that uses the appointment-based model of medication refill pickup and consultation in an effort to improve adherence and health outcomes. It adds to Omnicell’s existing offerings, which include its SureMed medication adherence packaging and related automation.
"By understanding the clinical and fiscal challenges these providers face, Omnicell now offers a portfolio of products and services that address the need for improved adherence across the continuum of care," Omnicell VP and GM medication adherence Troy Hilsenroth said. "We are excited about the strong potential of the combined entity, and to continue our mission of improving adherence and patient outcomes."
BDSI names VP business development
RALEIGH, N.C. — BioDelivery Sciences International has named a new VP business development. BDSI announced Wednesday that it had chosen Peter Ginsberg, who has more than 25 years of business development and related experience, for the role.
Ginsberg was most recently the head of business development for United Therapeutics, which he joined following his time at the North Carolina Biotechnology Center, where he was president of business and technology development. His other experience includes time overseeing acquisitions and licensing transactions as VP business development and strategic planning at SurModics. Ginsberg also spent 15 years working in healthcare investment.
"We are very pleased to have Peter join BDSI given the depth and level of experience he brings as we look to enhance our focus on business development opportunities, particularly given the recent reacquisition of Belbuca," BDSI president and CEO Mark A. Sirgo said. "This hire will allow us to augment our efforts behind business opportunities for Belbuca and Bunavail both outside as well as inside the U.S."
The company recently reacquired the rights to Belbuca from Endo, which is shifting its U.S. branded business’s focus away from pain products.
J&J, Actelion Pharmaceuticals talks end as Sanofi reportedly emerges as potential buyer
NEW BRUNSWICK, N.J. — A potential acquisition of Actelion Pharmaceuticals by Johnson & Johnson is now less likely to take place. Slightly more than two weeks after the two companies confirmed they were in discussion about a potential acquisition of Actelion, J&J said the talks have ended.
The company on Wednesday said “Johnson & Johnson was not able to reach an agreement that it believed would create adequate value for its shareholders.”
In a separate statement, Actelion said it was “engaged in discussions with another party regarding a possible strategic transaction,” with various reports saying the new party is Sanofi, according to sources close to the discussions.
“There can be no certainty at this point that any transaction will result,” Actelion said.
Loading Post Please Wait...